BMS, AstraZeneca Join Forces in $7B Combo Deal for Amylin
Bristol Myers Squibb Co., of New York, will realize operating synergies and tax benefits in addition to gaining access to Amylin Pharmaceuticals Inc.'s GLP-1 franchise, executives said in a Monday morning conference call regarding the pharma giant's acquisition of San Diego-based Amylin and partnership agreement with AstraZeneca plc.
To continue reading subscribe now to BioWorld Asia (formerly International)
Learn More about BioWorld Asia (formerly International)
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.